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Abstract 
 Background: Observational associations between cannabis and 
schizophrenia are well documented, but ascertaining causation is more challenging. 
We used Mendelian randomization (MR), utilizing publicly available data as a method 
for ascertaining causation from observational data. 
 Methods: We performed bi-directional two-sample MR using summary level 
genomewide data from the International Cannabis Consortium (ICC) and the 
Psychiatric Genomics Consortium (PGC2). Single nucleotide polymorphisms (SNPs) 
associated with cannabis initiation (P < 10-5) and schizophrenia (P < 5x10-8) were 
combined using an inverse-variance weight fixed-effects approach. We also used 
height and education genomewide-association study data, representing negative and 
positive control analyses. 
 Results: There was some evidence consistent with a causal effect of 
cannabis initiation on risk of schizophrenia (OR 1.04 per doubling odds of cannabis 
initiation, 95% CI 1.01, 1.07, P = 0.019). There was strong evidence consistent with a 
causal effect of schizophrenia risk on likelihood of cannabis initiation (OR 1.10 per 
doubling of the odds of schizophrenia, 95% CI 1.05, 1.14, P = 2.64 × 10-5).  Findings 
were as predicted for the negative control (height OR 1.00, 95% CI 0.99 to 1.01, P = 
0.90) but weaker than predicted for the positive control (years in education OR 0.99, 
95% CI 0.97 to 1.00, P = 0.066) analyses. 
 Conclusions: Our results provide some that cannabis initiation increases the 
risk of schizophrenia, though the size of the causal estimate is small. We find 
stronger evidence that schizophrenia risk predicts cannabis initiation, possibly as 
genetic instruments for schizophrenia are stronger than for cannabis initiation. 
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Assessing causality in associations between cannabis use and schizophrenia: 
A 2-sample Mendelian randomization study 
 
Introduction 
It is clear from human experimental studies that tetrahydrocannabinol (THC) 
intoxication can induce transient psychotic experiences (D'Souza et al., 2004). 
However, whether chronic cannabis use is causally associated with psychotic 
disorders such as schizophrenia is harder to ascertain (Gage et al., 2013, Gage et 
al., 2016a). A systematic review and meta-analysis (Moore et al., 2007) of 
longitudinal studies found evidence for a modest association between cannabis and 
later psychotic outcomes. However, the authors noted that the studies that adjusted 
for more potential confounding factors found that the point estimates attenuated to a 
greater degree than those adjusting for fewer, indicating that residual confounding 
could still be present. Some studies (Callaghan et al., 2012, Rossler et al., 2012), 
although not all (Gage et al., 2014), conducted since this meta-analysis have also 
found evidence of an association between cannabis use and later psychotic 
experiences or schizophrenia. As well as these observational studies, studies have 
been undertaken to investigate the genetic relationships between cannabis and 
schizophrenia. Power and colleagues (Power et al., 2014) found that a genetic risk 
score for schizophrenia predicted cannabis use in a sample of 2,082 healthy 
individuals. Verweij and colleagues (Verweij et al., in press) used LD-score 
regression to investigate the genetic correlation to investigate this association, and 
found evidence of a genetic correlation between lifetime cannabis use and risk of 
schizophrenia. This could be interpreted as shared genetic aetiology, but could also 
reflect a causal association between schizophrenia and risk of cannabis use (Gage et 
al., 2015).   
Observational epidemiology alone cannot allow researchers to determine 
causality. Residual confounding and reverse causation are difficult or impossible to 
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rule out, and associations that appear robust observationally are sometimes shown 
to be spurious when experimentally tested (Davey Smith and Ebrahim, 2001). A 
further difficulty in conducting observational studies to investigate the association 
between cannabis use and psychosis is that it is not possible to rule out the impact of 
psychotic phenomena occurring during intoxication in regular users due to the long 
half-life of THC (Huestis et al., 1992). One technique that can allow causal inference 
from observational data is Mendelian randomization (MR). It has been described in 
detail elsewhere (Davey Smith and Hemani, 2014, Gage et al., 2016b); briefly, if 
genetic variants can be identified that robustly predict an exposure of interest, these 
can be used as unconfounded proxies for that exposure. Associations between the 
variants and the outcome of interest can thus provide evidence of causation whilst 
(subject to certain assumptions) eliminating problems of confounding or reverse 
causation. A recent genomewide association study (GWAS) of cannabis initiation 
(Stringer et al., 2016) did not find any single nucleotide polymorphisms (SNPs) that 
reached genomewide significance, but identified a number of SNPs with weaker 
evidence of association with cannabis initiation. 
Two-sample MR allows for the use of publicly available summary data, where 
variant-exposure associations are identified from one GWAS, and variant-outcome 
associations from another (Burgess et al., 2015b). This can provide the large sample 
sizes required to provide adequate power to identify the small effect sizes of causal 
effects of common genetic variants in such studies. The current study uses two-
sample MR to assess the likelihood of a causal association between cannabis 
initiation and schizophrenia, and Egger regression (Bowden et al., 2015) to 
investigate whether any association observed is due to pleiotropic effects of SNPs 
rather than causal effects of cannabis on schizophrenia. We also use two-sample MR 
with two other outcomes, years in education and height, as positive and negative 
controls respectively. Evidence of association between cannabis and a positive 
control (where causal effects are more strongly established), and lack of evidence of 
5 
 
association with a negative control (where causal effects are implausible) add 
support to causal interpretations. We chose education as a positive control as 
previous epidemiological evidence has suggested a probable causal association 
between cannabis and educational attainment (Meier et al., 2012). We chose height 
as a negative control outcome because cannabis is unlikely to have a causal effect 
on height since cannabis use is not common before mid- to late-adolescence 
(Eastwood, 2013).  
 
Methods 
The International Cannabis Consortium (ICC) GWAS, across the genome, 
explained 13-20% of the observed phenotypic variation of ever use of cannabis 
(Stringer et al., 2016). Although no genomewide-significant SNPs were identified, 
153 SNPs were associated with cannabis initiation (ever/never use of cannabis) at P 
< 10-5. A number of these SNPs were in high linkage disequilibrium. Where R2 > 0.9, 
one SNP was randomly selected and the other highly correlated SNPs were removed 
from the analyses. 22 SNPs remained after this pruning, and a further SNP was 
removed due to poor quality (Vink, 2016, personal communication). The final 21 
SNPs are listed in Table 1. Correlations r2 < 0.9 were included in the analysis as a 
correlation matrix (Burgess et al., 2015b) (listed in Supplementary Table 1). 
These 21 SNPs were then extracted from the schizophrenia Psychiatric 
Genetics Consortium (PGC2) GWAS (Schizophrenia-Working-Group-of-the-
Psychiatric-Genomics-Consortium, 2014), a GWAS of educational attainment by the 
Social Science Genetics Association Consortium (SSGAC) (Rietveld et al., 2013) and 
the Genetic Investigation of Anthropometric Traits (GIANT) (Wood et al., 2014) 
GWAS of height. All 21 were in the schizophrenia GWAS, 8 were in the education 
GWAS, and 9 were in the height GWAS. We used the PhenoScanner tool (Staley et 
al., 2016) (http://phenoscanner.medschl.cam.ac.uk) to identify proxy SNPs using 
R2>0.9 correlations calculated in European-descent individuals from 1000 Genomes 
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Phase 3, and a further 4 were identified, meaning that 12 SNPs were available for 
the cannabis-education and cannabis-height associations. These SNPs were used 
for the main analyses for the positive and negative controls. The full 21 SNPs were 
used for the main analysis to investigate the association between cannabis initiation 
and schizophrenia. We also conducted a sensitivity analysis restricting the cannabis-
schizophrenia analysis to the same 12 SNPs used for the positive and negative 
control analyses. We used PhenoScanner to obtain estimates of the mutual 
correlations between variants, and a correlation matrix was included in the regression 
analysis model (Burgess et al., 2015a) (correlation matrix shown in Supplementary 
Table 1). 
To assess the likelihood of a causal association between schizophrenia and 
cannabis initiation (schizophrenia risk predicting likelihood of cannabis initiation), we 
extracted 128 SNPs independently associated with schizophrenia at genomewide 
significance. These SNPs explain approximately 18% of the observed variance in 
schizophrenia risk (Schizophrenia-Working-Group-of-the-Psychiatric-Genomics-
Consortium, 2014). Of the 128 SNPs, 107 were also present in the GWAS of 
cannabis initiation (listed in Supplementary Table 2). 
 
Effect of cannabis initiation on schizophrenia risk 
Log odds ratios and standard errors for the associations between the 
significant (P < 10-5) SNPs and cannabis initiation were recorded. The same SNPs 
were then identified in the PGC2 GWAS of schizophrenia, and the corresponding log 
odds ratios and standard errors were recorded. The SNP-exposure and SNP-
outcome coefficients were combined using an inverse-variance weighted approach to 
give an overall estimate of causal effect. This is equivalent to a weighted regression 
of the SNP-outcome coefficients on the SNP-exposure coefficients with the intercept 
constrained to zero.  
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The results of the analyses were converted to odds ratios. Given that 
schizophrenia is a binary outcome, the resulting causal effect estimate represents the 
odds for schizophrenia risk per unit increase in the log odds ratio for cannabis 
initiation, and is therefore somewhat hard to interpret. ORs have therefore been 
converted (by multiplying log odds ratios by 0.693 and then exponentiating) in order 
to represent the odds ratio per doubling in odds of the binary exposure.  
 
Effect of schizophrenia risk on cannabis initiation 
 As above, the 107 SNPs associated with schizophrenia were extracted from 
the GWAS schizophrenia, and then identified in the GWAS of cannabis initiation, and 
log odds ratios and standard errors recorded. The SNP-exposure and SNP-outcome 
coefficients were combined as described above. 
 
Positive and negative controls 
The 12 cannabis initiation SNPs (or proxies where appropriate) were 
identified in GWAS of education and height, and beta coefficients and standard 
errors recorded, as described above. Although these GWASs were conducted on 
continuous outcomes, the resulting coefficients have been transformed as described 
above (multiplied by 0.693) for consistency. 
 
Sensitivity analyses 
We used MR-Egger regression to formally test for potential violations of 
Mendelian randomization assumptions. This method relaxes the assumption that the 
effects of genetic variants on the outcome operate entirely via the exposure, by 
allowing an intercept term in the weighted regression described above. The intercept 
parameter represents the overall pleiotropic effect of the SNPs on the outcome (i.e., 
a direct effect on the outcome rather than via the exposure, which would violate MR 
assumptions). If the intercept deviates from the null, this provides evidence that there 
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may be bias in the standard causal estimate due to pleiotropy. The beta coefficient 
for this analysis provides a causal estimate, assuming that the pleiotropic effect of 
SNPs on the outcome is not correlated with the associations between the SNPs and 
the exposure (MR Egger is described in more detail in Corbin et al., 2016).  
With correlated genetic variants, the inverse-variance weighted regression 
model is extended to a generalized weighted regression model, as described 
previously (Burgess et al., 2015a). For MR-Egger regression, the same generalized 
weighted regression analysis was undertaken except including an intercept term in 
the regression model. The genetic associations with the outcome (�̂௒) were 
regressed on the genetic associations with the exposure (cannabis initiation, �̂௑) 
using inverse-variance weights. The regression model is: �̂௒ = �0 + ���̂௑ + ɛ 
where �0 is the intercept term and �� is the Egger causal estimate and ɛ is an error 
term with zero mean and covariance matrix Ω. The weighting matrix Ω has terms Ω�భ�మ = �௒�భ�௒�మρ�భ�మ, where �௒� is the standard error of the genetic association with 
the outcome for the jth SNP, and ρ�భ�మ is the correlation between the j1th and j2th 
SNPs. This regression gives the same estimates as standard Egger regression with 
uncorrelated variants when the correlations between different variants are all zero. 
As another sensitivity analysis, the cannabis-schizophrenia association was 
also assessed using the 12 SNPs available for the education and height analyses, in 
order to allow a direct comparison. Given the potentially weak instruments used to 
predict cannabis initiation, we ran a further sensitivity analysis where we 
systematically removed each SNP from the analysis, in order to check the 
robustness of the findings. 
 Finally, we performed a calculation in order to estimate the relative risk of 
schizophrenia predicted by our upper confidence bound (UCB) comparing an 
individual who is likely to use cannabis (50% probability of initiation) with an 
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individual with a low probability of smoking cannabis (10% probability of initiation) 
using the calculation: exp((log(0.5/(1-0.5))-log(0.1/(1-0.1))*log(UCB/0.693). 
 
Results 
Effect of cannabis initiation on schizophrenia risk 
 In 36,989 schizophrenia cases and 113,075 controls, an MR analysis using 
21 SNPs associated (P < 10-5) with cannabis initiation indicated a small association 
with schizophrenia case status (OR 1.04, 95% CI 1.01 to 1.07 per doubling of the 
odds of initiation, P = 0.019). 
 
Effect of schizophrenia risk on cannabis initiation 
 In 14,388 individuals who have used cannabis in their lifetime and 17,942 
non-cannabis users, an MR analysis using 107 SNPs associated with schizophrenia 
at genome-wide significance (P < 5 × 10-8) provided strong evidence of an 
association between schizophrenia case status and lifetime cannabis initiation (OR 
1.10, 95% CI 1.05 to 1.14 per doubling of the odds of schizophrenia, P = 2.64 × 10-5). 
 
Positive and negative controls 
In 126,599 individuals, an MR analysis using 12 SNPs associated (P < 10-5) 
with cannabis initiation indicated a weak association with fewer years in education 
(OR 0.99, 95% CI 0.97 to 1.00 per doubling of the odds of initiation, P = 0.066) (the 
positive control). In 253,288 individuals, an MR analysis using these SNPs found no 
evidence of an association with height (OR 1.00, 95% CI 0.99 to 1.01, P = 0.90) (the 
negative control). These results are shown in Table 2. 
 
Sensitivity analyses 
A sensitivity MR-Egger regression indicated very little evidence of pleiotropy 
in the association between cannabis and schizophrenia using the full list of 21 SNPs 
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(intercept OR 0.99, 95% CI 0.98 to 1.01, P = 0.50). The strength of evidence for a 
causal association was considerably weaker in this analysis with wider CIs (OR 1.01, 
95% CI 0.93 to 1.10, P = 0.815), although not inconsistent with the findings from the 
primary analysis. 
There was no strong evidence of pleiotropy in the association between 
schizophrenia (exposure) and cannabis initiation (outcome) (intercept OR 1.00, 95% 
CI 0.98 to 1.01, P = 0.52). The point estimate was larger in this analysis as compared 
to the standard MR approach, however the strength of evidence of an association 
was weaker (OR 1.17, 95% CI 0.96 to 1.43, P = 0.13). The Egger plots for these 
analyses are shown in the supplementary materials (supplementary figures 1 and 2). 
MR-Egger regression suggested weak evidence of pleiotropy in the positive 
and negative control outcome analyses using 12 SNPs (intercept OR education 0.99, 
95% CI 0.97 to 1.00, P = 0.18; height 0.99, 95% CI 0.98 to 1.00, P = 0.093). The 
causal estimate from the MR-Egger regression for the association of cannabis 
initiation with years of education was slightly larger than for the main analysis, 
although the strength of evidence was very similar (OR 0.94, 95% CI 0.88 to 1.00, P 
= 0.062). The causal estimate from the MR-Egger regression analysis of cannabis 
initiation and height provided weak evidence for cannabis initiation being associated 
with shorter height (OR 0.95, 95% CI 0.88 to 1.01, P = 0.095), but was still consistent 
overall with the lack of association indicated in the primary analysis. These results 
are shown in Table 3. 
 When the association between cannabis initiation and schizophrenia risk was 
restricted to the 12 SNPs available for the education and height analyses, the 
resulting association was similar to the primary analysis, although confidence 
intervals were wider (OR 1.03, 95% CI 0.99 to 1.08, P = 0.15). This is shown in 
Tables 2 and 3. 
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 When we systematically removed each SNP that predicted cannabis initiation 
in turn there was no evidence that the size of the effect was being driven by one SNP 
(Supplementary Figure 3).  
 Finally, we calculated the relative risk of schizophrenia for an individual who is 
likely to smoke cannabis (50% probability of initiation) to be at most 24% higher 
compared with an individual with a low probability of smoking cannabis (10% 
probability of initiation) based on the upper confidence interval for the causal effect 
estimate. 
 
Discussion 
 Our results provide some evidence in support of the hypothesis that cannabis 
initiation increases the risk of schizophrenia, although the size of the causal estimate 
is small. Our findings therefore do not contradict the current observational literature 
suggesting an association between cannabis initiation and schizophrenia of a 
moderate size, and may suggest any true causal effect size is smaller still. Given the 
small effect sizes generally seen in the observational data (Moore et al., 2007) 
particularly when considering cannabis initiation phenotypes, and in these results 
using a different methodology, this converging evidence supports the theory that 
although cannabis use might be a risk factor for schizophrenia, any effect cannabis 
initiation has is likely to be small. For example, based on the upper bound of the 95% 
CI from our primary analysis, an individual who is more likely to smoke cannabis 
(50% probability of initiation) has at most a 24% higher relative risk of suffering from 
schizophrenia compared with an individual with a low probability of smoking cannabis 
(10% probability of initiation). However, these results are unlikely to be directly 
comparable to the observational studies in terms of comparing effect sizes, 
particularly with regard to heavier use of cannabis, or use of different strains of 
cannabis where ratios of cannabinoids may differ. The ratio of THC and cannabidiol 
(CBD) is likely to be particularly important in determining the psychotomimetic 
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properties of cannabis (D'Souza et al., 2004, Iseger and Bossong, 2015), although 
genetic variants that index the strength of cannabis used have not been identified as 
yet. 
 We found strong evidence in support of the reverse causation hypothesis, 
that schizophrenia risk predicts likelihood of cannabis initiation. These findings are 
consistent with a recent study that showed genetic predisposition for schizophrenia 
was associated with increased use of cannabis (Power et al., 2014). The authors of 
that study interpreted their findings as evidence for shared genetic aetiology between 
cannabis use and schizophrenia; however, an alternate interpretation, supported by 
the more directional analyses reported here, is that schizophrenia risk increases the 
risk of cannabis use. Our study cannot provide information about potential 
mechanisms through which this could happen. Causation could be via either 
biological or social mechanisms. For example, people with a higher genetic risk for 
schizophrenia could be more predisposed to try cannabis because they experience 
more pleasurable or positive effects of intoxication, or because they are more likely to 
associate with people who use cannabis (Nordsletten et al., 2016). However, these 
explanations remain speculative, although could be tested in further research, for 
example using a recall-by-genotype design. The findings from the positive and 
negative control analyses were broadly consistent with our prediction; our results 
suggest that cannabis initiation is associated with fewer years in education (though 
with weaker evidence than predicted), while cannabis initiation does not predict 
height. 
 
Strengths and limitations 
 MR studies allow stronger evidence of causality than is possible from 
observational epidemiology, which is a strength of this study. Utilising both MR and 
positive and negative control designs allows for a triangulation of approaches with 
different limitations (Gage et al., 2016b). A particular strength of two-sample MR is 
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that it can provide the large sample sizes required to identify the small effect sizes 
that are likely when using SNPs as proxies to study complex phenotypes. However, 
there are a number of limitations to our study. Firstly, none of the SNPs used to 
predict cannabis initiation reached genomewide significance in the original GWAS 
(Stringer et al., 2016). As these SNPs are not strong predictors of cannabis initiation 
(and some may represent false positives), it is likely that our effect size estimates will 
be overly-conservative. The weak evidence of association with our positive control 
could be explained by the weakness of our genetic instrument. While these SNPs did 
not reach genomewide significance in the cannabis initiation GWAS, they were 
nevertheless associated with initiation at P < 10-5. Inferences and estimates from a 
MR analysis may still be valid even if genetic variants are included that are not truly 
associated with the exposure; their inclusion is equivalent to adding noise to a 
genetic risk score. Including false positive variants is not ideal as it reduces power 
and could introduce pleiotropic variants to the analysis. However, as we do not know 
which variants are true associations and which are false positives, our approach 
makes the best possible use of the available data. We also conduct MR Egger 
sensitivity analyses, which are more robust to pleiotropy.  
Secondly, there is a small overlap in the cohorts included in the schizophrenia 
and cannabis GWAS, as both include data from the Estonia Genome Centre cohort 
(EGCUT). ECGUT data makes up 2.3% of the PGC2 dataset, and approximately 
10% of the Cannabis Consortium dataset. The true overlap is 1,500 individuals 
(Esko, 2016, personal communication). A small overlap such as this is unlikely to 
result in substantial bias (Burgess et al., 2016). Large overlap would bias the results 
in the direction of the observational association (and therefore could lead to an 
overestimation of the effect). We reran our main analyses in both directions using a 
version of the PGC2 data with this sample removed. Results did not change from 
those presented.  
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Thirdly, and perhaps more problematic, is that it is not clear what the 
cannabis initiation phenotype used in the Cannabis Consortium GWAS actually 
represents; participants were asked ‘Have you ever used cannabis?’, so there is no 
distinction between having tried cannabis once and having used it every day for 
many years. If there is a causal association between cannabis and schizophrenia, it 
is more likely that exposure intensity would be the relevant risk factor. 
Observationally, the association between ever use of cannabis and later psychosis is 
much weaker than for heavy cannabis use (Moore et al., 2007). Furthermore, those 
who choose to try cannabis (rather than become regular or heavy users) might be 
more impulsive or risk taking than those who never try it, and this GWAS could 
therefore be a measure of that or other related phenotypes, rather than cannabis 
initiation per se. Our lack of understanding of the function of the genetic variants 
identified in the cannabis initiation GWAS and their role in cannabis metabolism 
means that we do not understand the mechanism by which they impact on cannabis 
use.  
A recent GWAS of cannabis use identified 3 SNPs at genomewide 
significance in a sample of 14754 participants (Sherva et al., 2016). However, this 
GWAS conflates cannabis initiation with dependence phenotypes, which would make 
interpretation of any association we might find challenging. Also, given our inability to 
stratify participants in the schizophrenia PGC sample by cannabis use status, we 
deemed it inappropriate to use these SNPs as genetic influences on cannabis 
dependence cannot occur unless a person has used cannabis. This analysis needs 
to be conducted in cannabis users separately from non-users; if the association 
between cannabis and schizophrenia is causal, there should be an association 
observed between the cannabis dependence SNPs and schizophrenia in cannabis 
dependent subjects, but no association observed in non-users.  
A further limitation relates to the nature of schizophrenia. Since the vast 
majority of the population do not have schizophrenia, we are making an assumption 
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that genetic predictors of schizophrenia also have an impact in the general 
population. There is evidence that psychotic symptoms exist on a continuum 
(Linscott and van Os, 2013), which would mean this is an appropriate assumption to 
make. It has also been found that genetic risk for schizophrenia predicts childhood 
psychopathology (Jones et al., 2016).  
Finally, a further limitation is our choice of positive and negative controls. 
Whilst weak evidence of association may be due to the use of a weak genetic 
instrument, as discussed above, it is also possible that our assumption of causality 
between cannabis and education is misplaced. Since we began our analyses, two 
studies have been published suggesting that the association between cannabis and 
education may be more strongly confounded than previously believed (Jackson et al., 
2016, Mokrysz et al., 2016). With regards to height as a negative control, there is 
some evidence of a negative correlation between height and schizophrenia risk, that 
could be due to pleiotropy (Bacanu et al., 2013). Identifying appropriate positive and 
negative controls is extremely challenging when investigating complex phenotypes 
such as substance use and mental health. However, in the interests of completeness 
we present both our positive and negative control analyses as originally conceived. 
Given that schizophrenia and cannabis initiation are both complex 
phenotypes, likely to be influenced by multiple genetic and environmental risk factors, 
a consideration of pleiotropy is important. We conducted MR Egger analyses to 
formally test for biological pleiotropy (where genetic variants have a direct impact on 
more than one phenotype). Biological pleiotropy violates the assumptions of MR, but 
we find only weak evidence of biological pleiotropy. It is distinct from mediated 
pleiotropy (whereby a genetic variant may have a mediated impact on a later 
phenotype via a direct effect on an upstream phenotype), which does not violate the 
assumptions of MR. A recent paper (Verweij et al., in press) used LD-score 
regression to assess the association between cannabis use and schizophrenia, and 
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found evidence of a genetic correlation. This could mean shared genetic architecture, 
but it is also consistent with a causal relationship in one or both directions. 
 
Conclusion 
Our results provide some evidence that cannabis initiation might be causally 
associated with odds of developing schizophrenia, using two-sample MR to support 
stronger causal inference, although the size of the association is small. The results 
provide stronger evidence that schizophrenia risk predicts likelihood of cannabis 
initiation, but the weakness of the currently-available genetic instrument for cannabis 
use limits our interpretation of these results. Whilst stronger instruments are likely to 
be identified with increasing GWAS sample sizes, future GWAS studies of 
schizophrenia should prioritise recording cumulative cannabis exposure in cases and 
controls to allow the causal association between heaviness of cannabis use and 
schizophrenia to be investigated in stratified samples. 
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Table 1: List of SNPs (correlated < 0.9) associated with cannabis initiation (P < 10-5), and proxies where used. 
 
rs number Chromosome Nearest gene 
(within 100k 
base pairs) 
beta (se) 
cannabis 
initiation 
beta (se) 
schizophrenia 
Proxy r2 for proxy 
rs7675351 4 SCOC 0.15 (0.03) 0.00 (0.02)   
rs7700636 5 NR3C1 0.15 (0.03) 0.01 (0.01)   
rs17237367 15 RORA 0.12 (0.03) 0.01 (0.01)   
rs4984458* 15 - 0.10 (0.02) -0.01 (0.01) rs12906344 1.000 
rs4984460 15 - 0.12 (0.03) -0.01 (0.01)   
rs3738226 1 RCSD1 0.10 (0.02) 0.00 (0.01)   
rs74944517* 2 LOC129656 0.29 (0.06) 0.02 (0.02) rs1526674 1.000 
rs2326313* 3 CADM2 0.10 (0.02) -0.01 (0.01) rs9819830 1.000 
rs6840574 4 - 0.15 (0.03) 0.01 (0.01)   
rs1554927 8 CALB1 0.10 (0.02) 0.02 (0.01)   
rs12789616 11 NCAM1 0.09 (0.02) 0.02 (0.01)   
rs8041045* 15 - 0.10 (0.02) 0.00 (0.01) rs12439562 0.971 
rs73067624 * 1 KCNT2 0.18 (0.04) 0.02 (0.02)   
rs12518098 * 5 ZSWIM6 0.10 (0.02) 0.02 (0.01)   
rs353253 * 5 PCYOX1L 0.11 (0.03) -0.01 (0.01)   
rs8102250 * 19 CRX 0.13 (0.03) 0.01 (0.01)   
rs113019398 * 20 LINC00687 0.17 (0.04) -0.03 (0.02)   
rs2033867 * 2 SP9 0.24 (0.05) 0.05 (0.02)   
rs13063578 * 3 SETD2 0.11 (0.02) 0.02 (0.01)   
rs7107987 * 11 CHID1 0.27 (0.06) 0.01 (0.01)   
rs12313672 * 12 RNA5SP356 0.14 (0.03) 0.02 (0.01)   
 
* SNPs not in education / height GWAS 
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Table 2: Associations between cannabis initiation and various outcomes and schizophrenia and cannabis initiation using 2-sample MR. 
 
Exposure Outcome OR* 95% CI p-value N SNPs 
Cannabis initiation Schizophrenia (binary outcome) 1.04† 1.01 to 1.07 0.019 21 
Cannabis initiation Education (years) 0.99† 0.97 to 1.00 0.066 12 
Cannabis initiation Height (z-score) 1.00† 0.99 to 1.01 0.901 12 
Cannabis initiation Schizophrenia (binary outcome) 1.03† 0.99 to 1.08 0.145 12# 
Schizophrenia Cannabis initiation (binary outcome) 1.10 1.05 to 1.14 2.64E-05 107 
 
* per doubling in odds of exposure; † correlated likelihood method used; # restricted number of SNPs to be comparable to positive/negative 
control analyses 
 
 
  
24 
 
Table 3: Egger regression analyses showing intercept and causal estimate values for associations between cannabis initiation and various 
outcomes and schizophrenia and cannabis initiation. 
 
Exposure Outcome  OR* 95% CI p N SNPs 
Cannabis 
initiation 
Schizophrenia 
(binary outcome) 
Intercept 
Causal estimate 
0.99† 
1.01† 
0.98 to 1.01 
0.93 to 1.10 
0.50 
0.815 21 
Cannabis 
initiation 
Education 
(years) 
Intercept 
Causal estimate 
0.99† 
0.94† 
0.99 to 1.00 
0.88 to 1.00 
0.182 
0.062 12 
Cannabis 
initiation 
Height 
(z-score) 
Intercept 
Causal estimate 
0.99† 
0.95† 
0.98 to 1.00 
0.88 to 1.01 
0.093 
0.095 12 
Cannabis 
initiation 
Schizophrenia 
(binary outcome) 
Intercept 
Causal estimate 
1.00† 
1.01† 
0.97 to 1.03 
0.88 to 1.17 
0.801 
0.854 12
# 
Schizophrenia Cannabis initiation  (binary outcome) 
Intercept 
Causal estimate 
1.00 
1.17 
0.98 to 1.01 
0.96 to 1.43 
0.524 
0.128 107 
 
* per doubling in odds of exposure; † correlated likelihood method used; # restricted number of SNPs to be comparable to positive/negative 
control analyses 
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Supplementary material 
Supplementary Table 1: Correlation matrix of SNPs associated with cannabis 
initiation. 
 rs4984460 rs4984458 rs8041045 
rs4984460 1 0.18 0.12 
rs4984458 0.18 1 0.65 
Rs8041045 0.12 0.65 1 
 
r2 shown; all other SNPs were not correlated with each other. 
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Supplementary Table 2: List of SNPs associated with schizophrenia (P < 5x10-8). 
 
SNP ID  Chr SNP ID Chr SNP ID Chr SNP ID Chr 
rs12129573 1 rs4330281 3 rs10503253 8 rs12887734 14 
rs11210892 1 rs832187 3 rs73229090 8 rs4702 15 
rs77149735* 1 rs17194490 3 rs36068923 8 rs8042374 15 
rs10803138 1 rs1106568 4 rs6984242 8 rs12903146 15 
rs7523273 1 rs35518360 4 rs7819570 8 rs56205728 15 
rs76869799* 1 rs215411 4 rs11139497 9 rs190065944 15 
chr1_8424984_D* 1 rs10520163 4 rs11191419 10 rs950169 15 
chr1_243881945_I* 1 rs4391122 5 chr10_104957618_I* 10 rs12148337 15 
rs1702294 1 rs111294930 5 rs7893279 10 rs12691307 16 
rs140505938 1 rs16867576 5 rs7907645 10 rs9922678 16 
rs4648845 1 rs11740474 5 rs55833108 10 rs8044995 16 
rs1498232 1 rs12522290 5 rs55661361 11 rs12325245 16 
rs14403 1 chr5_140143664_I* 5 rs75059851 11 rs7405404 16 
rs6670165 1 rs2973155 5 rs9420 11 rs8082590 17 
rs59979824 2 rs3849046 5 rs11027857 11 rs4523957 17 
rs11685299 2 rs1501357 5 rs77502336 11 rs9636107 18 
rs6704768 2 rs10043984 5 chr11_46350213_D* 11 chr18_52749216_D* 18 
rs6434928 2 rs4388249 5 rs2514218 11 rs72934570 18 
rs3768644 2 rs79212538 5 rs12421382 11 rs715170 18 
rs6704641 2 rs115329265 6 rs10791097 11 rs78322266* 18 
rs2909457 2 chr6_84280274_D* 6 rs2239063 12 rs2053079 19 
rs75575209 2 rs117074560 6 rs324017 12 rs2905426 19 
chr2_200825237_I* 2 rs1339227 6 rs679087 12 rs56873913 19 
chr2_146436222_I* 2 rs6466055 7 rs2007044 12 rs6065094 20 
chr2_149429178_D* 2 rs12704290 7 rs2851447 12 rs7267348 20 
rs11693094 2 rs7801375 7 rs4240748 12 rs9607782 22 
rs11682175 2 chr7_2025096_I* 7 rs4766428 12 chr22_39987017_D* 22 
rs7432375 3 chr7_24747494_D* 7 rs10860964 12 rs6002655 22 
rs9841616 3 rs13240464 7 rs12826178* 12 rs1023500 22 
chr3_180594593_I* 3 rs3735025 7 rs2693698 14 rs12845396* 23 
rs75968099 3 rs211829 7 rs2332700 14 rs1378559* 23 
rs2535627 3 rs4129585 8 rs2068012 14 rs5937157* 23 
 
* SNPs not in cannabis initiation GWAS. Note: Chr, chromosome. 
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Supplementary figure 1: MR Egger regression of cannabis initiation predicting risk of 
schizophrenia. 
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Supplementary Figure 2: MR Egger regression risk of schizophrenia predicting 
cannabis initiation. 
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Supplementary Figure 3: Forest plot showing the effect size and confidence intervals 
of Mendelian randomization associations between cannabis initiation and risk of 
schizophrenia, systematically removing each cannabis initiation SNP in turn 
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